Filana Therapeutics adds biopharma executive Jill Quigley to board
The Austin-based company named Quigley a Class I director as it prepares to begin a Phase 2a study of simufilam in TSC-related epilepsy.
SEC filing
3 stories
The Austin-based company named Quigley a Class I director as it prepares to begin a Phase 2a study of simufilam in TSC-related epilepsy.
SEC filing
Filana Therapeutics said patient screening for its Phase 2a simufilam study in TSC-related epilepsy is expected to begin by the first quarter of 2027 after the FDA lifted a clinical hold in September 2026.
SEC filing
Filana Therapeutics said patient screening for a Phase 2a trial in TSC-related epilepsy is expected to begin by the first quarter of 2027.
SEC filing